Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Orthopaedics and Related Research®
Published in: Clinical Orthopaedics and Related Research® 1/2017

01-01-2017 | Symposium: 2016 Knee Society Proceedings

No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA

Authors: John W. Barrington, MD, Roger H. Emerson, MD, Scott T. Lovald, PhD, Adolph V. Lombardi, MD, Keith R. Berend, MD

Published in: Clinical Orthopaedics and Related Research® | Issue 1/2017

Login to get access

Abstract

Background

Opioid analgesics have been a standard modality for postoperative pain management after total knee arthroplasty (TKA) but are also associated with increased risk of nausea, pruritus, vomiting, respiratory depression, prolonged ileus, and cognitive dysfunction. There is still a need for a method of anesthesia that can deliver effective long-term postoperative pain relief without incurring the high cost and health burden of opioids and nerve blocks.

Questions/purposes

(1) Is liposomal bupivacaine-based periarticular injection (PAI) more effective than morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA? (2) Do patients treated with liposomal bupivacaine-based PAI experience fewer opioid-related adverse events compared with patients treated with morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA?

Methods

This multicenter, blind trial randomized 119 patients undergoing TKA with spinal anesthesia to receive spinal anesthesia plus periarticular injection with liposomal bupivacaine (40 patients), spinal anesthesia with bupivacaine plus intrathecal morphine (41 patients) but no liposomal bupivacaine injection, or spinal anesthesia with bupivacaine (38 patients) and no liposomal bupivacaine injection. The two groups that did not receive periarticular liposomal bupivacaine did receive periarticular injection with ropivacaine, and all three groups had ketorolac (30 mg) plus epinephrine (1:1000) in the periarticular injections. Patients in all three groups received identical perioperative multimodal analgesic and antiemetic drugs. All patients were analyzed in the group to which they were randomized and no patients were lost to followup. The primary study endpoints were visual analog score (VAS) for pain and narcotic use during postoperative day 1. Secondary endpoints included side effects associated with narcotic administration during the hospital stay.

Results

Mean VAS pain in the liposomal bupivacaine PAI group was lower than that for the ropivacaine PAI group at 6 hours (1.8 ± 2.1 versus 3.3 ± 2.3, p = 0.005, mean difference: 1.5, 95% confidence interval [CI], 0.5–2.5) and 12 hours (1.5 ± 2.0 versus 3.3 ± 2.4, p < 0.001, mean difference: 1.8, 95% CI, 0.8–2.8) after surgery. The morphine spinal group had lower pain compared with the liposomal bupivacaine PAI group at 6 hours (0.9 ± 1.8 versus 1.8 ± 2.1, p = 0.035, mean difference: 1.0, 95% CI, 0.1–1.8), but there was no difference at 12 hours (0.8 ± 1.5 versus 1.5 ± 2.0, p = 0.086, mean difference: 0.7, 95% CI, −0.1 to 1.5). The magnitude of the differences at 6 and 12 hours are near the lower end of minimal clinically important differences reported in the literature, and thus the improvement shown in this study may only represent a small clinical improvement. Both the liposomal bupivacaine group (13% [five of 40]) and the ropivacaine group (5% [two of 38]) had fewer incidents of itching (pruritus) than the spinal morphine group (38% [15 of 41]) (p = 0.001).

Conclusions

This prospective multicenter three-arm blind randomized controlled trial showed potentially improved pain control at 6 and 12 hours in the liposomal bupivacaine and intrathecal morphine groups compared with the ropivacaine group at the cost of much higher incidences of pruritus (itching) in the intrathecal morphine group. Based on these results, we prefer the use of PAI with liposomal bupivacaine as an alternative to spinal anesthesia with intrathecal morphine as a result of similar postoperative pain control and the potential for reducing adverse events.

Level of Evidence

Level I, therapeutic study.
Literature
1.
Affas F, Nygards EB, Stiller CO, Wretenberg P, Olofsson C. Pain control after total knee arthroplasty: a randomized trial comparing local infiltration anesthesia and continuous femoral block. Acta Orthop. 2011;82:441–447.CrossRefPubMedPubMedCentral
2.
Asik I, Goktug A, Gulay I, Alkis N, Uysalel A. Comparison of bupivacaine 0.2% and ropivacaine 0.2% combined with fentanyl for epidural analgesia during labour. Eur J Anaesthesiol. 2002;19:263–270.CrossRefPubMed
3.
Atherton MJ, Feeg VD, el-Adham AF. Race, ethnicity, and insurance as determinants of epidural use: analysis of a national sample survey. Nurs Econ. 2004;22:6–13.
4.
Azim SA, Sangster R, Curcio C, Coleman D, Shah U, Zhang S, Reinsel RA, Glass PSA, Nicholson J, Benveniste H. Characterization of Patients with difficult-to-treat acute pain following total knee arthroplasty using multi-modal analgesia. Open Pain J. 2013;6:1–6.CrossRef
5.
Bagsby DT, Ireland PH, Meneghini RM. Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty. J Arthroplasty. 2014;29:1687–1690.CrossRefPubMed
6.
Barrington JW, Olugbode O, Lovald S, Ong K, Watson H, Emerson RH. Liposomal bupivacaine: a comparative study of more than 1,000 total joint arthroplasty cases. Orthop Clin North Am. 2015;46:469–477.CrossRefPubMed
7.
Beaulieu P, Babin D, Hemmerling T. The pharmacodynamics of ropivacaine and bupivacaine in combined sciatic and femoral nerve blocks for total knee arthroplasty. Anesth Analg. 2006;103:768–774.CrossRefPubMed
8.
Beaupre LA, Johnston DB, Dieleman S, Tsui B. Impact of a preemptive multimodal analgesia plus femoral nerve blockade protocol on rehabilitation, hospital length of stay, and postoperative analgesia after primary total knee arthroplasty: a controlled clinical pilot study. Scientific World Journal. 2012;2012:1–6.CrossRef
9.
Bergese SD, Onel E, Morren M, Morganroth J. Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile. Reg Anesth Pain Med. 2012;37:145–151.CrossRefPubMed
10.
Bergese SD, Ramamoorthy S, Patou G, Bramlett K, Gorfine SR, Candiotti KA. Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia. J Pain Res. 2012;5:107–116.CrossRefPubMedPubMedCentral
11.
Bertini L, Mancini S, Di Benedetto P, Ciaschi A, Martini O, Nava S, Tagariello V. Postoperative analgesia by combined continuous infusion and patient-controlled epidural analgesia (PCEA) following hip replacement: ropivacaine versus bupivacaine. Acta Anaesthesiol Scand. 2001;45:782–785.CrossRefPubMed
12.
Bertini L, Tagariello V, Mancini S, Ciaschi A, Posteraro CM, Di Benedetto P, Martini O. 0.75% and 0.5% ropivacaine for axillary brachial plexus block: a clinical comparison with 0.5% bupivacaine. Reg Anesth Pain Med. 1999;24:514–518.PubMed
13.
Bird SB, Dickson EW. Clinically significant changes in pain along the visual analog scale. Ann Emerg Med. 2001;38:639–643.CrossRefPubMed
14.
15.
Busch CA, Shore BJ, Bhandari R, Ganapathy S, MacDonald SJ, Bourne RB, Rorabeck CH, McCalden RW. Efficacy of periarticular multimodal drug injection in total knee arthroplasty. A randomized trial. J Bone Joint Surg Am. 2006;88:959–963.PubMed
16.
Capdevila X, Barthelet Y, Biboulet P, Ryckwaert Y, Rubenovitch J, d’Athis F. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology. 1999;91:8–15.CrossRefPubMed
17.
Carr DB, Reines HD, Schaffer J, Polomano RC, Lande S. The impact of technology on the analgesic gap and quality of acute pain management. Reg Anesth Pain Med. 2005;30:286–291.CrossRefPubMed
18.
Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74:102–112.CrossRefPubMed
19.
Chen PP, Chui PT, Ma M, Gin T. A prospective survey of patients after cessation of patient-controlled analgesia. Anesth Analg. 2001;92:224–227.CrossRefPubMed
20.
Cohen SM. Extended pain relief trial utilizing infiltration of Exparel®, a long-acting multivesicular liposome formulation of bupivacaine: a Phase IV health economic trial in adult patients undergoing open colectomy. J Pain Res. 2012;5:567–572.CrossRefPubMedPubMedCentral
21.
Coley KC, Williams BA, DaPos SV, Chen C, Smith RB. Retrospective evaluation of unanticipated admissions and readmissions after same day surgery and associated costs. J Clin Anesth. 2002;14:349–353.CrossRefPubMed
22.
Crosby E, Sandler A, Finucane B, Writer D, Reid D, McKenna J, Friedlander M, Miller A, O’Callaghan-Enright S, Muir H, Shukla R. Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarean section. Can J Anaesth. 1998;45:1066–1071.CrossRefPubMed
23.
Crowley C, Dowsey MM, Quinn C, Barrington M, Choong PF. Impact of regional and local anaesthetics on length of stay in knee arthroplasty. ANZ J Surg. 2012;82:207–214.CrossRefPubMed
24.
Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012;28:1609–1615.CrossRefPubMed
25.
Datta S, Camann W, Bader A, VanderBurgh L. Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. Anesthesiology. 1995;82:1346–1352.CrossRefPubMed
26.
Davidson EM, Barenholz Y, Cohen R, Haroutiunian S, Kagan L, Ginosar Y. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg. 2010;110:1018–1023.CrossRefPubMed
27.
Dihle A, Helseth S, Kongsgaard UE, Paul SM, Miaskowski C. Using the American Pain Society’s patient outcome questionnaire to evaluate the quality of postoperative pain management in a sample of Norwegian patients. J Pain. 2006;7:272–280.CrossRefPubMed
28.
Dihle A, Helseth S, Paul SM, Miaskowski C. The exploration of the establishment of cutpoints to categorize the severity of acute postoperative pain. Clin J Pain. 2006;22:617–624.CrossRefPubMed
29.
30.
Eandi JA, de Vere White RW, Tunuguntla HS, Bohringer CH, Evans CP. Can single dose preoperative intrathecal morphine sulfate provide cost-effective postoperative analgesia and patient satisfaction during radical prostatectomy in the current era of cost containment? Prostate Cancer Prostatic Dis. 2002;5:226–230.
31.
Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am. 2004;86:963–974.CrossRefPubMed
32.
Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. 2000;88:287–294.CrossRefPubMed
33.
Fishbain DA, Gao J, Lewis JE, Zhang L. At Completion of a multidisciplinary treatment program, are psychophysical variables associated with a VAS improvement of 30% or more, a minimal clinically important difference, or an absolute VAS score improvement of 1.5 cm or more? Pain Med. 2016;17:781–789.PubMed
34.
35.
Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28:776–788.CrossRefPubMed
36.
Green CR, Anderson KO, Baker TA, Campbell LC, Decker S, Fillingim RB, Kalauokalani DA, Lasch KE, Myers C, Tait RC, Todd KH, Vallerand AH. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med. 2003;4:277–294.CrossRefPubMed
37.
Griffin RP, Reynolds F. Extradural anaesthesia for caesarean section: a double-blind comparison of 0.5% ropivacaine with 0.5% bupivacaine. Br J Anaesth. 1995;74:512–516.CrossRefPubMed
38.
Haas E, Onel E, Miller H, Ragupathi M, White PF. A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation. Am Surg. 2012;78:574–581.PubMed
39.
Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A. National hospital discharge survey: 2007 summary. Natl Health Stat Report. 2010:1–20, 24.
40.
Hayes MHS, Patterson DG. Experimental development of the graphic rating method. Psychol Bull. 1921;18:98–99.
41.
Hickey R, Hoffman J, Ramamurthy S. A comparison of ropivacaine 0.5% and bupivacaine 0.5% for brachial plexus block. Anesthesiology. 1991;74:639–642.
42.
43.
Joshi GP, Cushner FD, Barrington JW, Lombardi AV Jr, Long WJ, Springer BD, Stulberg BN. Techniques for periarticular infiltration with liposomal bupivacaine for the management of pain after hip and knee arthroplasty: a consensus recommendation. J Surg Orthop Adv. 2015;24:27–35.CrossRefPubMed
44.
Joyce CR, Zutshi DW, Hrubes V, Mason RM. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol. 1975;8:415–420.CrossRefPubMed
45.
46.
Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618–1625.CrossRefPubMed
47.
Kelly AM. Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain? Acad Emerg Med. 1998;5:1086–1090.CrossRefPubMed
48.
Kerr DR, Kohan L. Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients. Acta Orthop. 2008;79:174–183.CrossRefPubMed
49.
Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33:383–391.CrossRefPubMed
50.
Knudsen K, Beckman Suurkula M, Blomberg S, Sjovall J, Edvardsson N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth. 1997;78:507–514.CrossRefPubMed
51.
Lansky D, Nwachukwu BU, Bozic KJ. Using financial incentives to improve value in orthopaedics. Clin Orthop Relat Res. 2012;470:1027–1037.CrossRefPubMed
52.
Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB. Disposition kinetics of ropivacaine in humans. Anesth Analg. 1989;69:736–738.CrossRefPubMed
53.
Marcet JE, Nfonsam VN, Larach S. An extended pain relief trial utilizing the infiltration of a long-acting multivesicular liposome formulation of bupivacaine, EXPAREL (IMPROVE): a Phase IV health economic trial in adult patients undergoing ileostomy reversal. J Pain Res. 2013;6:549–555.CrossRefPubMedPubMedCentral
54.
Marques EM, Blom AW, Lenguerrand E, Wylde V, Noble SM. Local anaesthetic wound infiltration in addition to standard anaesthetic regimen in total hip and knee replacement: long-term cost-effectiveness analyses alongside the APEX randomised controlled trials. BMC Med. 2015;13:151.CrossRefPubMedPubMedCentral
55.
McGlade DP, Kalpokas MV, Mooney PH, Chamley D, Mark AH, Torda TA. A comparison of 0.5% ropivacaine and 0.5% bupivacaine for axillary brachial plexus anaesthesia. Anaesth Intensive Care. 1998;26:515–520.
56.
Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, Kajdasz DK, Walker DJ, Chappell AS. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res. 2011;63:821–826.CrossRef
57.
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:1–28.CrossRef
58.
Morrison LM, Emanuelsson BM, McClure JH, Pollok AJ, McKeown DW, Brockway M, Jozwiak H, Wildsmith JA. Efficacy and kinetics of extradural ropivacaine: comparison with bupivacaine. Br J Anaesth. 1994;72:164–169.CrossRefPubMed
59.
Morrison RS, Magaziner J, McLaughlin MA, Orosz G, Silberzweig SB, Koval KJ, Siu AL. The impact of post-operative pain on outcomes following hip fracture. Pain. 2003;103:303–311.CrossRefPubMed
60.
Ng A, Hall, F, Atkinson, A, Kong, K, Hahn, A. Bridging the analgesic gap. Acute Pain. 2000;3:1–6.CrossRef
61.
Oderda G. Challenges in the management of acute postsurgical pain. Pharmacotherapy. 2012;32:6S–11S.CrossRefPubMed
62.
Oderda GM, Evans RS, Lloyd J, Lipman A, Chen C, Ashburn M, Burke J, Samore M. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manage. 2003;25:276–283.CrossRefPubMed
63.
Oderda GM, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse events on outcomes in selected surgical patients. J Pain Palliat Care Pharmacother. 2013;27:62–70.CrossRefPubMed
64.
Oderda GM, Said Q, Evans RS, Stoddard GJ, Lloyd J, Jackson K, Rublee D, Samore MH. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41:400–406.CrossRefPubMed
65.
Olive DJ, Barrington MJ, Simone SA, Kluger R. A randomised controlled trial comparing three analgesia regimens following total knee joint replacement: continuous femoral nerve block, intrathecal morphine or both. Anaesth Intensive Care. 2015;43:454–460.PubMed
66.
Parvataneni HK, Shah VP, Howard H, Cole N, Ranawat AS, Ranawat CS. Controlling pain after total hip and knee arthroplasty using a multimodal protocol with local periarticular injections: a prospective randomized study. J Arthroplasty. 2007;22:33–38.CrossRefPubMed
67.
Pavlin DJ, Chen C, Penaloza DA, Buckley FP. A survey of pain and other symptoms that affect the recovery process after discharge from an ambulatory surgery unit. J Clin Anesth. 2004;16:200–206.CrossRefPubMed
68.
Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000;93:1123–1133.PubMed
69.
Pogatzki-Zahn EM, Schnabel A, Zahn PK. Room for improvement: unmet needs in postoperative pain management. Exp Rev Neurother. 2012;12:587–600.CrossRef
70.
Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116:248–273.
71.
72.
Richman JM, Liu SS, Courpas G, Wong R, Rowlingson AJ, McGready J, Cohen SR, Wu CL. Does continuous peripheral nerve block provide superior pain control to opioids? A meta-analysis. Anesth Analg. 2006;102:248–257.CrossRefPubMed
73.
Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8:283–291.CrossRefPubMed
74.
Scott DB, Lee A, Fagan D, Bowler GM, Bloomfield P, Lundh R. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg. 1989;69:563–569.PubMed
75.
Sharma S, Iorio R, Specht LM, Davies-Lepie S, Healy WL. Complications of femoral nerve block for total knee arthroplasty. Clin Orthop Relat Res. 2010;468:135–140.CrossRefPubMed
76.
Sinatra R, Bigham, M. The anatomy and pathophysiology of acute pain. In: Grass J, ed. Problems in Anesthesiology. Philadelphia, PA, USA: Lippincott-Raven; 1997.
77.
So JP, Wright JG. The use of three strategies to improve quality of care at a national level. Clin Orthop Relat Res. 2012;470:1006–1016.CrossRefPubMed
78.
Southworth S, Peters J, Rock A, Pavliv L. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain. Clin Ther. 2009;31:1922–1935.CrossRefPubMed
79.
Stahmer SA, Shofer FS, Marino A, Shepherd S, Abbuhl S. Do quantitative changes in pain intensity correlate with pain relief and satisfaction? Acad Emerg Med. 1998;5:851–857.CrossRefPubMed
80.
Syed HM, Green L, Bianski B, Jobe CM, Wongworawat MD. Bupivacaine and triamcinolone may be toxic to human chondrocytes: a pilot study. Clin Orthop Relat Res. 2011;469:2941–2947.CrossRefPubMedPubMedCentral
81.
Todd KH, Funk JP. The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med. 1996;3:142–146.CrossRefPubMed
82.
Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, Felson DT, Hajjaj-Hassouni N, Hochberg M, Logeart I, Matucci-Cerinic M, van de Laar M, van der Heijde D, Dougados M. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res. 2012;64:1699–1707.CrossRef
83.
Vogel JD. Liposome bupivacaine (EXPAREL®) for extended pain relief in patients undergoing ileostomy reversal at a single institution with a fast-track discharge protocol: an IMPROVE Phase IV health economics trial. J Pain Res. 2013;6:605–610.PubMedPubMedCentral
84.
Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol. 1993;20:557–560.PubMed
85.
Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain. 2002;3:159–180.CrossRefPubMed
86.
Writer WD, Stienstra R, Eddleston JM, Gatt SP, Griffin R, Gutsche BB, Joyce TH, Hedlund C, Heeroma K, Selander D. Neonatal outcome and mode of delivery after epidural analgesia for labour with ropivacaine and bupivacaine: a prospective meta-analysis. Br J Anaesth. 1998;81:713–717.CrossRefPubMed
87.
Wu CL, Naqibuddin M, Rowlingson AJ, Lietman SA, Jermyn RM, Fleisher LA. The effect of pain on health-related quality of life in the immediate postoperative period. Anesth Analg. 2003;97:1078–1085.CrossRefPubMed
Metadata
Title
No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA
Authors
John W. Barrington, MD
Roger H. Emerson, MD
Scott T. Lovald, PhD
Adolph V. Lombardi, MD
Keith R. Berend, MD
Publication date
01-01-2017
Publisher
Springer US
Published in
Clinical Orthopaedics and Related Research® / Issue 1/2017
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-016-4931-z

Other articles of this Issue 1/2017

Clinical Orthopaedics and Related Research® 1/2017 Go to the issue

Symposium: 2016 Knee Society Proceedings

Editorial Comment: 2016 Knee Society Proceedings

Letter to the Editor

Letter to the Editor: Editorial: How the Words We Use Affect the Care We Deliver

Symposium: 2016 Knee Society Proceedings

Can Preoperative Patient-reported Outcome Measures Be Used to Predict Meaningful Improvement in Function After TKA?

CORR Insights

CORR Insights®: Variations in the Innervation of the Long Head of the Triceps Brachii: A Cadaveric Investigation

Symposium: 2016 Knee Society Proceedings

No Difference Between Trabecular Metal Cones and Femoral Head Allografts in Revision TKA: Minimum 5-year Followup

Systematic Review

What Differences in Morphologic Features of the Knee Exist Among Patients of Various Races? A Systematic Review